Novasenta raises $40 million in Series A funding

Novasenta is an oncology drug developer that is using the human tumor microenvironment to develop new immunotherapies that enable the body’s own immune system to fight cancer. The company has developed a proprietary platform for single-cell RNA analysis of human tumor samples that combines advanced data mining and target validation capabilities to accelerate the journey from discovery to drug development. Novasenta announced the completion of a $40 million Series A financing led by venture capital firm UPMC Enterprises.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.